When people hear the word antipsychotic, they often picture severe psychiatric illness in adults. But in pediatric care—especially in autism—the story is very different, and honestly, far more complicated.
We’re in Chapter 3 of Behind the Wheel with Autism, the chapter where we discuss the effects of medications commonly used for autistic teens and adults. These medications are also used in very young children on the spectrum, and although this book is aimed at driving readiness, the medication bus starts years earlier so I’m including them here. We’re starting with one of the most widely discussed and least understood classes: antipsychotics.
What they’re actually prescribed for
In autism-related care, antipsychotics are primarily used for:
- irritability
- aggression
- severe mood dysregulation
- self-injury
- extreme behavioral outbursts
The two medications with FDA approval for irritability in autism are:
- Risperidone (Risperdal) is a second-generation or atypical antipsychotic medication used to treat schizophrenia, bipolar disorder, and irritability associated with autism. It works by rebalancing dopamine and serotonin in the brain to improve mood, thoughts, and behavior.
- Aripiprazole (Abilify) is an atypical antipsychotic medication used to treat schizophrenia, bipolar I disorder, irritability in autism, and as an add-on treatment for major depressive disorder. Aripiprazole acts by balancing neurotransmitters in the brain.
And yes—they can reduce intensity of meltdowns, aggression, and dangerous behaviors. And yes, it can be appropriate to prescribe them as there’s a higher rate of co-occurring psychiatric conditions among autistic people.
Allow me to perch on my soap box for a moment and point out the question that often gets skipped in clinical settings:
WHY are they irritable in the first place?
Because medication can quiet a fire without ever asking what sparked it.
And underneath it all is a question we still don’t ask enough:
Are we treating behavior—or are we treating the unmet needs that create the behavior? Before we fill that prescription, let’s ask ourselves: have we addressed the known gastrointestinal and immune dysfunction of the autism spectrum as we discussed in Chapter 2? The sensory challenges? The brain inflammation? Autism can be quite the package of co-occurring conditions, which can also include cerebral folate deficiency, Ehlers Danlos syndrome, mitochondrial dysfunction, methylation differences, and many more, which highlights the importance of thoughtful, individualized care.
I feel the best questions don’t start with “which” and “what”, as in:
- Which medication should we try?
- What dose should we use?
The best questions start with “why”:
- Why is he irritable?
- Why is she exhibiting distress behaviors?
- Why are they upset or angry?
If labile moods, irritability, and difficult behaviors are keeping you or your child from driving, you’re going to want to dip back into Chapter 2 and tend to the underlying health issues of the autism spectrum before going any further. Okay, I’m climbing off the soap box, I promise…
Meanwhile, let’s get back to the topic of antipsychotics.
Other medications you’ll often see used for behaviors
In real-world practice, many of these medications are used less for psychiatric diagnoses and more for behavioral stabilization or sedation effects.
Even beyond the two FDA-approved options, clinicians sometimes use:
- Quetiapine (Seroquel / Seroquel XR)
- Ziprasidone (Geodon, off-label)
- Olanzapine (Zyprexa, sometimes used, often sedating)
- Clonidine and Guanfacine (not antipsychotics, but often used for calming and impulse control)
- Trazodone (commonly used for sleep and sedation effects)
Here’s the part most people don’t realize
Across large national datasets, most children receiving antipsychotics are not diagnosed with psychotic disorders.
Instead, the most common diagnoses are:
- ADHD
- disruptive behavior disorders
- mood dysregulation conditions
In fact, ADHD is often the leading diagnosis among children prescribed these medications, followed by oppositional defiant disorder (ODD) and conduct disorder.
These are not psychotic disorders. They are conditions rooted in behavioral and emotional regulation challenges. (Remember my mantra─biology, not behavior!)
Autism is part of the picture—but not the whole picture
Antipsychotics are FDA-approved for irritability in autism, which is why they are frequently used in this population.
But it’s important to be precise about what that means:
- They are not treating psychosis
- They are targeting behavior, aggression, and emotional dysregulation
In other words, they are being used to suppress symptoms, not necessarily cause.
And that distinction matters more than we often acknowledge.
The reality of off-label use
One of the most consistent findings in the literature:
Around 82% of pediatric antipsychotic use is off-label
That means most prescriptions are not for FDA-approved indications.
Even more concerning, some studies find:
- children with no clearly documented psychiatric diagnosis
- or diagnoses that don’t typically justify these medications
This is where the ethical and clinical debate intensifies.
The systems behind the prescription pad
In real-world practice, these medications are often prescribed under pressure—not just clinical decision-making in isolation.
Common drivers include:
- urgent safety concerns (aggression, self-injury, crisis behavior)
- overwhelmed caregivers and systems
- school pressure to stabilize behavior for placement
- long waitlists for behavioral therapy
- limited access to intensive supports
So the decision is often less:
“Is this the perfect medication?”
and more:
“What will keep this child safe and stable right now?”
The central tension
Here is the uncomfortable truth the literature keeps circling back to:
- Behavioral interventions are often the recommended first-line approach
- But they are frequently delayed, limited, or inaccessible at needed intensity
So clinicians are left choosing between:
- ideal care that is hard to access
vs - imperfect care that is immediately available
That gap shapes far more prescribing decisions than most people realize. Here in West Virginia where I live and practice, some counties have behavioral supports and therapies available and some have none, so it’s easy to see how we turn to medications for relief as a first choice. I’ll also point out from personal experience that an autism household experiencing behavioral difficulties can be chaotic and on the edge at all times, making getting to therapy appointments out of reach for many, again making medication a choice that is understandable if not ideal.
Bottom line
- Most children on antipsychotics are not psychotic
- The most common targets are behavioral and emotional dysregulation
- Off-label use is the norm, not the exception
- And prescribing is often driven by systems pressure as much as clinical indication
This is not a simple story of “overuse” or “misuse.” It is a story of complexity, scarcity of resources, sometimes just plain old fatigue, and competing harms.
Whatever the reason you’re on them, join me next time as we take a closer look at the effects and side effects of antipsychotics—and how they may support driving readiness in some cases, while creating barriers in others.